Interojo Co

Interojo Co Equity Growth

The Year-over-Year Equity Growth of Interojo Co (119610.KQ) as of Nov 20, 2026 is -7.60 %. In the previous year, Year-over-Year Equity Growth was -9.49 % — a change of -19.92% (higher).

Equity Growth

-7.60 %

YoY

-19.92%

Last updated:

Year-over-Year Equity Growth of Interojo Co is 2025 -7.60 % . Year-over-Year Equity Growth of Interojo Co was 2024 -9.49 % . It decreases by -19.92% higher compared to the previous year.

The Interojo Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
18.46 KRW
Jan 1, 2019
8.40 KRW
Jan 1, 2020
2.64 KRW
Jan 1, 2021
31.52 KRW
Jan 1, 2022
6.59 KRW
Jan 1, 2023
-0.73 KRW
Jan 1, 2024
-9.49 KRW
Jan 1, 2025
-7.60 KRW
The Interojo Co Equity Growth history
YEAREquity GrowthYoY
-7.60 %-19.92%
-9.49 %+1,198.22%
-0.73 %-111.09%
6.59 %-79.09%
31.52 %+1,093.54%
2.64 %-68.55%
8.40 %-54.52%
18.46 %+42.65%
12.94 %-42.10%
22.35 %+6.59%
20.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interojo Co Stock analysis

What does Interojo Co do? Interojo Co Ltd manufactures and sells contact lenses including silicone hydrogel lenses, sodium hyaluronate lenses, frequent replacement lenses, conventional lenses, toric lenses, multifocal vision lenses, color lenses, therapy and bandage lenses, and rigid gas permeable (RGP) contact lenses along with solutions. The company distributes its products in domestic and overseas markets, targeting both retail consumers and healthcare providers who purchase lenses for patient use. Its product range caters to diverse vision correction needs, from standard to specialized medical applications, with solutions supporting lens care and usage. The firm's primary revenue streams come from the sale of contact lenses and associated solutions to customers in both domestic and international markets. Products like silicone hydrogel lenses and RGP contact lenses represent key offerings for everyday wear and specialized vision correction, while therapy and bandage lenses serve medical applications requiring professional oversight. The company's domestic market presence complements its overseas distribution, ensuring broad accessibility across different customer segments. Interojo Co Ltd's business model focuses on direct sales of its comprehensive product portfolio to end-users and healthcare institutions. The company's product lines address various vision correction scenarios, from routine daily use with frequent replacement lenses to advanced medical needs with therapy lenses. By maintaining a diverse range of contact lenses and solutions, the company serves both consumer and professional markets without relying on third-party partnerships or additional services. Interojo Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interojo Co stock

Year-over-Year Equity Growth of Interojo Co is -7.60 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Interojo Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Interojo Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Interojo Co

All Key Metrics — Interojo Co